Chonluten
Respiratory / GIAlso known as: Glu-Asp-Gly, EDG
Mechanism
A tripeptide bioregulator targeting bronchial and GI mucosal tissue. It normalizes mucin production and epithelial cell function. Related to Bronchogen (another Khavinson respiratory peptide) but with broader mucosal activity covering both airways and the digestive tract.
Technical detail
Synthetic tripeptide (Glu-Asp-Gly) bioregulator for bronchopulmonary and gastrointestinal mucosal epithelium. Normalizes expression of MUC genes (mucin production) and promotes differentiation of goblet cells and ciliated epithelial cells. In chronic bronchitis models, restores mucociliary clearance. Khavinson's framework proposes that the EDG sequence has affinity for gene regulatory regions in mucosal epithelial cells. Studies show normalization of sIgA secretion and improved epithelial barrier function. Related to Bronchogen (Ala-Glu-Asp-Leu) but broader tissue specificity.
Effects
## Respiratory System — Lung Parenchyma [Tier 3 — Limited Human Data, Russian Clinical Studies] Chonluten (Thr-Glu-Asp-Gly, tetrapeptide) is a Khavinson bioregulator targeting lung parenchymal tissue and gastrointestinal mucosa. Unlike Bronchogen (which targets bronchial epithelium), Chonluten is described as acting on the deeper lung tissue — alveolar epithelial cells, pneumocytes, and the interstitial compartment. In Russian clinical studies, it reportedly improves gas exchange efficiency, normalizes surfactant production, and reduces inflammatory infiltration in alveolar tissue of elderly patients with chronic lung conditions. ## Gastrointestinal System [Tier 3 — Limited Human Data] Chonluten reportedly normalizes GI mucosal function, particularly in the small intestine. Proposed effects include restoration of villous architecture, normalization of digestive enzyme secretion, and improved nutrient absorption. In Russian clinical studies on elderly patients, it was associated with improved GI symptoms and normalized intestinal permeability markers. ## Immune System [Tier 3 — Preclinical/Limited Human Data] Reported to modulate mucosal-associated lymphoid tissue (MALT) function in both the respiratory and GI tracts. Proposed normalization of local IgA production and T-cell populations in mucosal tissues.
Practitioner Guide
## Clinical Context Chonluten, like Bronchogen, originates from the Khavinson bioregulator program. It is positioned as a lung parenchyma and GI mucosa bioregulator. Not approved by any Western regulatory agency. ### Typical Protocols (From Russian Clinical Literature) - **Oral capsules:** 10 mg daily for 10-30 days. Cycled similarly to other bioregulators. - **Combination approach:** Most commonly combined with Bronchogen (bronchial epithelium) for comprehensive respiratory support. The pairing is: Chonluten = deep lung tissue, Bronchogen = airways. - **For GI applications:** Combined with Svetinorm (liver) and Stamakort (stomach) bioregulators. - **Target populations:** Elderly patients with chronic lung disease, post-pneumonia recovery, chronic GI conditions with malabsorption. ### Practitioner Considerations - Same evidence limitations as Bronchogen — limited to Russian clinical literature, no Western regulatory-grade trials. - The dual respiratory + GI targeting is attributed to the shared embryological origin of respiratory and GI mucosa from endoderm. - Oral bioavailability questions apply as with all Khavinson tetrapeptides. - No reported serious adverse effects, but safety database is small. - Use as adjunctive support only — do not replace evidence-based respiratory or GI treatments. - May be of interest to practitioners who see elderly patients with concurrent respiratory and digestive complaints, where the dual-tissue targeting could theoretically provide additive benefit.
Research Summary
## Tier 1 — Strong Clinical Evidence - None. No Western regulatory approval. No international Phase III RCTs. ## Tier 2 — Moderate Evidence - Russian clinical studies report improved pulmonary function and gas exchange parameters in elderly patients with chronic lung conditions after 10-30 day oral courses - Reported improvements in GI absorption markers and mucosal integrity in elderly patients with chronic digestive conditions ## Tier 3 — Preclinical/Theoretical - Cell culture studies showing Chonluten modulates gene expression in alveolar epithelial cells and intestinal mucosal cells - Proposed DNA-binding mechanism at promoter regions of genes involved in mucosal cell differentiation and function - Animal model data (aged rats) showing improved lung histology and intestinal villous architecture - The dual tissue targeting (lung + GI) aligned with endodermal developmental biology is theoretically interesting but not validated by rigorous mechanistic studies - All research from single institute — independent replication needed